




A Di	MSO treate	d proliferati	ing cells	Etoposide	SnCs	IR+V	eliparib SnC	s	IR SnC	s	GSK4	161364 SnC	s	
Scr CT26														IGFBP6 CXCL1 CCL9 CCL5 sTNF-RII
в	А	в	с	D	E	F	G	н		J	к	L	м	N
1	POS	POS	NEG	NEG	Blank	axl	BLC	CD30L	CD30/TNFRSF8		CRG-2	CTACK	CXCL16	Eotaxin
2	POS	POS	NEG	NEG	Blank	axl	BLC	CD30L	CD30/TNFRSF8	CD40	CRG-2	СТАСК	CXCL16	Eotaxin
3	Eotaxin-2	FAS ligand	Fractalkine	G-CSF	GM-CSF	IFN-gamma	IGF-BP-3	IGF-BP-5	IGF-BP-6	IL1-alpha	IL1-beta	IL2	IL3	IL3 Rb
4	Eotaxin-2	FAS ligand	Fractalkine	G-CSF	GM-CSF	IFN-gamma	IGF-BP-3	IGF-BP-5	IGF-BP-6	IL1-alpha	IL1-beta	IL2	IL3	IL3 Rb
5	IL4	IL5	IL6	IL9	IL10	IL12-p40/p70	IL12-p70	IL13	IL17	KC (CXCL1)	Leptin R	Leptin	LIX (CXCL5)	L-Selectin
6	IL4	IL5	IL6	IL9	IL10	IL12-p40/p70	IL12-p70	IL13	IL17	KC (CXCL1)	Leptin R	Leptin	LIX (CXCL5)	L-Selectin
7	Lymphotactin	MCP-1	MCP-5	M-CSF	MIG (CXCL9)	MIP-1-alpha	MIP-1-gamma (CCL9)	MIP-2	MIP-3-beta	MIP-3-alpha (CCL20)	PF4	P-Selectin	RANTES (CCL5)	SCF
8	Lymphotactin	MCP-1	MCP-5	M-CSF	MIG (CXCL9)	MIP-1-alpha	MIP-1-gamma (CCL9)	MIP-2	MIP-3-beta	MIP-3-alpha (CCL20)	PF4	P-Selectin	RANTES (CCL5)	SCF
9	SDF-1-alpha	TARC	TCA-3	TECK	TIMP-1	TNF-alpha	sTNF RI	sTNF RII	TPO	VCAM-1	VEGF	Blank	Blank	POS
10	SDF-1-alpha	TARC	TCA-3	TECK	TIMP-1	TNF-alpha	sTNF RI	sTNF RII	TPO	VCAM-1	VEGF	Blank	Blank	POS



Liu Y, et al. J Immunother Cancer 2023; 11:e005862. doi: 10.1136/jitc-2022-005862





DC cocultured with: DMSO treated 4T1 R+DMSO SnCs R+Veliparib SnCs Etoposide SnCs





% Proliferative cells


% Proliferative cells






































Α


Figure S18





+ -+





10

8

6

0

С	CD8	Perforin	DAPI/Overlay
Untreated			
Vaccine			
a-PD-L1			
Vaccine+α-PD-L1			

D	CD8	Granzyme B	DAPI/Overlay
Untreated			
Vaccine			
α-PD-L1			
Vaccine+α-PD-L1			and and a second

